A&O Shearman advises on initial public offering of Ceribell, Inc.

Ceribell is a commercial-stage medical device company selling a novel point-of-care EEG platform that uses AI-powered algorithms to enable rapid diagnosis and continuous monitoring of patients with neurological conditions. The highly successful transaction is seen as an important step towards re-opening the med-tech IPO market in the United States, which has largely been dormant for the past three years.

The transaction further reflects A&O Shearman’s strength and expertise in healthcare equity capital markets. A&O Shearman advised on 25 healthcare IPOs, for a combined total of USD4.51 billion in gross proceeds within the last decade. We have also advised on 26 healthcare follow-on equity offerings in the same time frame, for a combined total of over USD6.06bn in gross proceeds.

The A&O Shearman team was led by U.S. capital markets partner Ilir Mujalovic (partner, New York), with key support from Katya Bogdanov (associate, Toronto), Stella Sun (associate, New York) and Kaz Watanabe (associate, New York).

JB Betker (partner, New York) and Austin Grossfeld (associate, New York) provided advice on intellectual property matters, Jennifer Morton (partner, New York) and Taylor Pugliese (associate, New York) provided advice on financial services regulatory matters, Matthew Behrens (counsel, New York) and Gina Marini (associate, New York) provided advice on executive compensation matters, and Lorenz Haselberger (partner, New York) and Anna Armao (associate, New York) provided tax advice.